CYTOMX THERAPEUTICS, INC. (NASDAQ:CTMX) Files An 8-K Other Events
Item 8.01.Other Events.
On June 28, 2017, CytomX Therapeutics, Inc. issued a press
release announcing the treatment of the first patient in the
PROCLAIM-CX-2009 study, a Phase 1/2 clinical trial evaluating
CX-2009 as monotherapy in patients with select advanced solid
tumors. The full text of the press release is furnished as
Exhibit 99.1 hereto.
|
Item 9.01 |
Financial Statements and Exhibits. |
Reference is made to the Exhibit Index attached hereto
CytomX Therapeutics, Inc. ExhibitEX-99.1 2 ctmx-ex991_6.htm EX-99.1 ctmx-ex991_6.htm EXHIBIT 99.1 CytomX Announces the First Patient Treated in Phase 1/2 PROCLAIM-CX-2009 Trial SOUTH SAN FRANCISCO,…To view the full exhibit click here About CYTOMX THERAPEUTICS, INC. (NASDAQ:CTMX)
CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company. The Company is engaged in the development of a class of antibody therapeutics based on its Probody technology platform. It uses its platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against a range of targets. A Probody therapeutic consists of three components produced as a single protein by standard antibody production methodology: an active anti-cancer antibody, a mask for the antibody and a protease-cleavable linker. Its Probody product candidate, CX-072, is directed against programmed death-ligand 1 (PD-L1). CX-072 is based on a monoclonal antibody targeting PD-L1. Its product candidate, CX-2009, is directed against the target CD-166. It is developing a programmed cell death protein 1 (PD-1) Probody therapeutic as an additional approach to block the PD-L1/PD-1 pathway. It is also conducting Integrin alpha-3 PDC program.